<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Carbamazepine: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i277.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i277.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i277.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i276.htm">Antiepileptics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1040.htm" title="Previous: Zonisamide">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i281.htm" title="Next: Ethosuximide">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i277">Carbamazepine</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Carbamazepine</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i551.htm">Acetazolamide</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by acetazolamide </b></td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>CNS side-effects of  carbamazepine possibly increased by alcohol </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of tricyclics (reduced plasma concentration and reduced effect)</b></td><td></td></tr><tr><td><a href="41001i1010.htm" name="_1010">Aprepitant</a></td><td> carbamazepine possibly reduces plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1214.htm" name="_1214">Boceprevir</a></td><td class="cBV"><b>avoidance of  carbamazepine advised by manufacturer of boceprevir (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i896.htm" name="_896">Bupropion</a></td><td> carbamazepine reduces plasma concentration of bupropion </td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  carbamazepine advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i469.htm" name="_469">Calcium-channel Blockers (dihydropyridines)</a></td><td> carbamazepine probably reduces effects of dihydropyridines </td><td></td></tr><tr><td><a href="41001i947.htm" name="_947">Caspofungin</a></td><td> carbamazepine possibly reduces plasma concentration of caspofungin—consider increasing dose of caspofungin</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of ciclosporin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>metabolism of  carbamazepine inhibited by cimetidine (increased plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by clarithromycin </b></td><td></td></tr><tr><td><a href="41001i408.htm" name="_408">Clonazepam</a></td><td> carbamazepine often reduces plasma concentration of clonazepam </td><td></td></tr><tr><td><a href="41001i865.htm" name="_865">Clopidogrel</a></td><td class="cBV"><b> carbamazepine possibly reduces antiplatelet effect of clopidogrel </b></td><td></td></tr><tr><td><a href="41001i364.htm" name="_364">Clozapine</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of clozapine (reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i484.htm" name="_484">Corticosteroids</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of corticosteroids (reduced effect)</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of coumarins (reduced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1120.htm" name="_1120">Dabigatran Etexilate</a></td><td> carbamazepine possibly reduces plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i579.htm">Danazol</a></td><td class="cBV"><b>metabolism of  carbamazepine inhibited by danazol (increased risk of toxicity)</b></td><td></td></tr><tr><td><a href="41001i1091.htm" name="_1091">Darunavir</a></td><td> carbamazepine possibly reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i90.htm">Dextropropoxyphene</a></td><td class="cBV"><b>effects of  carbamazepine enhanced by dextropropoxyphene </b></td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b>effects of  carbamazepine enhanced by diltiazem </b></td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>increased risk of hyponatraemia when  carbamazepine given with diuretics </td><td></td></tr><tr><td><a href="41001i212.htm" name="_212">Doxycycline</a></td><td> carbamazepine accelerates metabolism of doxycycline (reduced effect)</td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b> carbamazepine possibly reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of both drugs reduced when  carbamazepine given with efavirenz </td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1205.htm" name="_1205">Eribulin</a></td><td> carbamazepine possibly reduces plasma concentration of eribulin </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1153.htm">Eslicarbazepine</a></td><td> carbamazepine possibly reduces plasma concentration of eslicarbazepine but risk of side-effects increased</td><td></td></tr><tr><td><a href="41001i281.htm" name="_281">Ethosuximide</a></td><td> carbamazepine possibly reduces plasma concentration of ethosuximide </td><td></td></tr><tr><td><a href="41001i1135.htm" name="_1135">Etravirine</a></td><td>avoidance of  carbamazepine advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i471.htm" name="_471">Felodipine</a></td><td> carbamazepine reduces effects of felodipine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td>plasma concentration of  carbamazepine possibly increased by fluconazole </td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by fluoxetine </b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by fluvoxamine </b></td><td></td></tr><tr><td><a href="41001i1019.htm" name="_1019">Fosamprenavir</a></td><td> carbamazepine possibly reduces plasma concentration of fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm" name="_1170">Gefitinib</a></td><td>avoidance of  carbamazepine advised by manufacturer of gefitinib </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> carbamazepine accelerates metabolism of haloperidol (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i933.htm" name="_933">Imatinib</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of imatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm" name="_398">Indinavir</a></td><td class="cBV"><b> carbamazepine possibly reduces plasma concentration of indinavir , also plasma concentration of carbamazepine possibly increased</b></td><td></td></tr><tr><td><a href="41001i1006.htm" name="_1006">Irinotecan</a></td><td> carbamazepine reduces plasma concentration of irinotecan and its active metabolite</td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by isoniazid (also possibly increased isoniazid hepatotoxicity)</b></td><td></td></tr><tr><td><a href="41001i684.htm">Isotretinoin</a></td><td>plasma concentration of  carbamazepine possibly reduced by isotretinoin </td><td></td></tr><tr><td><a href="41001i472.htm" name="_472">Isradipine</a></td><td> carbamazepine reduces effects of isradipine </td><td></td></tr><tr><td><a href="41001i302.htm" name="_302">Itraconazole</a></td><td> carbamazepine possibly reduces plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  carbamazepine possibly increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i283.htm">Lamotrigine</a></td><td> carbamazepine often reduces plasma concentration of lamotrigine , also plasma concentration of an active metabolite of carbamazepine sometimes raised (but evidence is conflicting)</td><td></td></tr><tr><td><a href="41001i1128.htm" name="_1128">Lapatinib</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of lapatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i913.htm">Levetiracetam</a></td><td>possible increased risk of  carbamazepine toxicity when given with levetiracetam </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>neurotoxicity may occur when  carbamazepine given with lithium without increased plasma concentration of lithium</td><td></td></tr><tr><td><a href="41001i922.htm" name="_922">Lopinavir</a></td><td> carbamazepine possibly reduces plasma concentration of lopinavir </td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>manufacturer of  carbamazepine advises avoid for 2 weeks after stopping MAOIs , also antagonism of anticonvulsant effect</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td> carbamazepine reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i254.htm" name="_254">Mianserin</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of mianserin </b></td><td></td></tr><tr><td><a href="41001i299.htm">Miconazole</a></td><td>plasma concentration of  carbamazepine possibly increased by miconazole </td><td></td></tr><tr><td><a href="41001i421.htm" name="_421">Midazolam</a></td><td> carbamazepine reduces plasma concentration of midazolam </td><td></td></tr><tr><td><a href="41001i823.htm" name="_823">Mirtazapine</a></td><td> carbamazepine reduces plasma concentration of mirtazapine </td><td></td></tr><tr><td><a href="41001i620.htm" name="_620">Muscle Relaxants, non-depolarising</a></td><td> carbamazepine antagonises muscle relaxant effect of non-depolarising muscle relaxants (accelerated recovery from neuromuscular blockade)</td><td></td></tr><tr><td><a href="41001i842.htm" name="_842">Nelfinavir</a></td><td> carbamazepine possibly reduces plasma concentration of nelfinavir </td><td></td></tr><tr><td><a href="41001i843.htm" name="_843">Nevirapine</a></td><td> carbamazepine reduces plasma concentration of nevirapine </td><td></td></tr><tr><td><a href="41001i474.htm" name="_474">Nicardipine</a></td><td> carbamazepine probably reduces effects of nicardipine </td><td></td></tr><tr><td><a href="41001i475.htm" name="_475">Nifedipine</a></td><td> carbamazepine probably reduces effects of nifedipine </td><td></td></tr><tr><td><a href="41001i476.htm" name="_476">Nimodipine</a></td><td>avoidance of  carbamazepine advised by manufacturer of nimodipine (plasma concentration of nimodipine possibly reduced)</td><td></td></tr><tr><td><a href="41001i636.htm" name="_636">Oestrogens</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td> carbamazepine accelerates metabolism of olanzapine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1045.htm" name="_1045">Ondansetron</a></td><td> carbamazepine accelerates metabolism of ondansetron (reduced effect)</td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td>plasma concentration of  carbamazepine sometimes reduced by oxcarbazepine (but concentration of an active metabolite of carbamazepine may be increased), also plasma concentration of an active metabolite of oxcarbazepine often reduced</td><td></td></tr><tr><td><a href="41001i1101.htm" name="_1101">Paliperidone</a></td><td> carbamazepine reduces plasma concentration of paliperidone </td><td></td></tr><tr><td><a href="41001i59.htm" name="_59">Paracetamol</a></td><td> carbamazepine possibly accelerates metabolism of paracetamol (also isolated reports of hepatotoxicity)</td><td></td></tr><tr><td><a href="41001i437.htm" name="_437">Phenobarbital</a></td><td> carbamazepine possibly increases plasma concentration of phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of both drugs often reduced when  carbamazepine given with phenytoin , also plasma concentration of phenytoin may be increased</td><td></td></tr><tr><td><a href="41001i1060.htm" name="_1060">Posaconazole</a></td><td class="cBV"><b> carbamazepine possibly reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i664.htm" name="_664">Progestogens</a></td><td class="cBV"><b> carbamazepine accelerates metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i824.htm">Quetiapine</a></td><td> carbamazepine accelerates metabolism of quetiapine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td> carbamazepine possibly reduces plasma concentration of reboxetine </td><td></td></tr><tr><td><a href="41001i1195.htm" name="_1195">Retigabine</a></td><td> carbamazepine possibly reduces plasma concentration of retigabine </td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>plasma concentration of  carbamazepine reduced by rifabutin </b></td><td></td></tr><tr><td><a href="41001i368.htm">Risperidone</a></td><td> carbamazepine accelerates metabolism of risperidone (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  carbamazepine possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i1102.htm" name="_1102">Rufinamide</a></td><td>plasma concentration of both drugs possibly reduced when  carbamazepine given with rufinamide </td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td> carbamazepine possibly reduces plasma concentration of saquinavir </td><td></td></tr><tr><td><a href="41001i605.htm" name="_605">Simvastatin</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of simvastatin—consider increasing dose of simvastatin</b></td><td></td></tr><tr><td><a href="41001i1144.htm">Stiripentol</a></td><td class="cBV"><b>plasma concentration of  carbamazepine increased by stiripentol </b></td><td></td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  carbamazepine advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> carbamazepine reduces plasma concentration of telithromycin (avoid during and for 2 weeks after carbamazepine)</b></td><td></td></tr><tr><td><a href="41001i734.htm" name="_734">Theophylline</a></td><td> carbamazepine accelerates metabolism of theophylline (reduced effect)</td><td></td></tr><tr><td><a href="41001i935.htm" name="_935">Thyroid Hormones</a></td><td> carbamazepine accelerates metabolism of thyroid hormones (may increase requirements for thyroid hormones in hypothyroidism)</td><td></td></tr><tr><td><a href="41001i857.htm" name="_857">Tiagabine</a></td><td> carbamazepine reduces plasma concentration of tiagabine </td><td></td></tr><tr><td><a href="41001i737.htm">Tibolone</a></td><td> carbamazepine accelerates metabolism of tibolone (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1203.htm" name="_1203">Ticagrelor</a></td><td> carbamazepine possibly reduces plasma concentration of ticagrelor </td><td></td></tr><tr><td><a href="41001i1055.htm" name="_1055">Tipranavir</a></td><td> carbamazepine possibly reduces plasma concentration of tipranavir </td><td></td></tr><tr><td><a href="41001i285.htm" name="_285">Topiramate</a></td><td> carbamazepine often reduces plasma concentration of topiramate </td><td></td></tr><tr><td><a href="41001i582.htm" name="_582">Toremifene</a></td><td> carbamazepine possibly accelerates metabolism of toremifene (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i106.htm" name="_106">Tramadol</a></td><td> carbamazepine reduces effects of tramadol </td><td></td></tr><tr><td><a href="41001i255.htm" name="_255">Trazodone</a></td><td> carbamazepine reduces plasma concentration of trazodone </td><td></td></tr><tr><td><a href="41001i1163.htm" name="_1163">Ulipristal</a></td><td class="cBV"><b>avoidance of  carbamazepine advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> carbamazepine reduces plasma concentration of valproate , also plasma concentration of active metabolite of carbamazepine increased</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>effects of  carbamazepine enhanced by verapamil </b></td><td></td></tr><tr><td><a href="41001i768.htm" name="_768">Vitamin D</a></td><td> carbamazepine possibly increases requirements for vitamin D </td><td></td></tr><tr><td><a href="41001i948.htm" name="_948">Voriconazole</a></td><td class="cBV"><b> carbamazepine possibly reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1040.htm" name="_1040">Zonisamide</a></td><td> carbamazepine reduces plasma concentration of zonisamide </td><td></td></tr></tbody></table><p>Carbamazepine belongs to <b>Antiepileptics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by SSRIs (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by tricyclics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i252.htm">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics possibly antagonised by tricyclic-related antidepressants (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by antipsychotics (convulsive threshold lowered)</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td>possible increased risk of convulsions when  antiepileptics given with chloroquine and hydroxychloroquine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td>anticonvulsant effect of  antiepileptics possibly antagonised by MAOIs (convulsive threshold lowered)</td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by mefloquine </b></td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td class="cBV"><b>possible increased risk of convulsions when  antiepileptics given with orlistat </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>avoid concomitant use of  antiepileptics with St John's wort </b></td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1040.htm">Previous: Zonisamide</a> | <a class="top" href="41001i277.htm#">Top</a> | <a accesskey="]" href="41001i281.htm">Next: Ethosuximide</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>